Status:
COMPLETED
Study of Tirzepatide in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
MALE
30-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepat...
Eligibility Criteria
Inclusion
- Overtly healthy males as determined by medical history, physical examination, and other screening procedures
- Have a body mass index (BMI) between 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive at screening
- Are willing to be available for the full duration of the study
Exclusion
- Have known allergies to tirzepatide or related compounds
- Have a medical condition or medical history that makes participation in the study unsafe or which may interfere in the interpretation of the results of the study
- Have had exposure to significant radiation within 12 months prior to dosing (for example, multiple x-ray or computed tomography \[CT\] scans, barium meal, being employed in a job requiring radiation exposure monitoring)
- Have participated in any clinical trial involving a radiolabeled substance within the past 12 months
Key Trial Info
Start Date :
July 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04311424
Start Date
July 28 2020
End Date
October 2 2020
Last Update
March 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Ltd
Leeds, West Yorkshire, United Kingdom, LS2 9LH